Travaux scientifiques

Prof. Dr. Meral Beksaç

912 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome

    Clinical Lymphoma, Myeloma and Leukemia, 2023

    DOI 10.1016/j.clml.2022.12.007 PMID 36610852 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  2. HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma

    Chemical Biology and Drug Design, 2023

    DOI 10.1111/cbdd.14237 PMID 37094820 13 citations (Europe PMC) Source : ORCID

  3. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study

    European Journal of Haematology, 2023

    DOI 10.1111/ejh.13981 PMID 37082839 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  4. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

    Research Square, 2023

    DOI 10.21203/rs.3.rs-3325630/v1 Texte intégral en libre accèsSource : ORCID

  5. Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

    Clinical Lymphoma Myeloma and Leukemia, 2023

    Source : ORCID

  6. Isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Research Square, 2023

    DOI 10.21203/rs.3.rs-3117230 Source : ORCID

  7. Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study

    Clinical Lymphoma Myeloma and Leukemia, 2023

    Source : ORCID

  8. LONG TERM OUTCOMES FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN DEPOSITION DISEASE: A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT

    Bone Marrow Transplantation, 2023

    Source : ORCID

  9. Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

    Blood, 2023

    DOI 10.1182/blood-2023-184367 Source : ORCID

  10. MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myeloma

    British Journal of Haematology, 2023

    Source : ORCID

  11. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet Oncology, 2023

    DOI 10.1016/s1470-2045(23)00223-1 PMID 37414019 115 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  12. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.21.02734 PMID 36413710 111 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  13. Phase 3 Randomized Study of Daratumumab (DARA) plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

    Blood, 2023

    Source : ORCID

  14. Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial

    Clinical Lymphoma Myeloma and Leukemia, 2023

    Source : ORCID

  15. Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma

    Clinical Lymphoma Myeloma and Leukemia, 2023

    Source : ORCID

  16. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, 2023

    DOI 10.1016/s1470-2045(23)00159-6 PMID 37269857 170 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  17. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, 2023

    DOI 10.1038/s41409-023-01915-7 PMID 36681775 7 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  18. Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation

    Journal of Clinical Apheresis, 2023

    DOI 10.1002/jca.22079 PMID 37503703 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  19. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

    The Lancet Haematology, 2023

    DOI 10.1016/s2352-3026(23)00218-1 PMID 37793772 36 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  20. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

    Journal of Oncology Pharmacy Practice, 2023

    DOI 10.1177/10781552221103551 PMID 36067063 14 citations (Europe PMC) Source : ORCID

  21. Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve LongTerm Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

    Blood, 2023

    DOI 10.1182/blood-2023-178533 4 citations (OpenAlex) Source : ORCID

  22. Upfront autologous transplantation still improving outcomes in patients with multiple myeloma

    The Lancet Haematology, 2023

    DOI 10.1016/s2352-3026(22)00360-x PMID 36529146 11 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  23. Validation of two international myeloma staging systems: second revision of ISS and mayo additive staging sytems (MASS) in an external cohort of Ankara University

    Clinical Lymphoma Myeloma and Leukemia, 2023

    Source : ORCID

  24. Werner helicase is required for proliferation and DNA damage repair in multiple myeloma

    Molecular Biology Reports, 2023

    DOI 10.1007/s11033-022-08178-3 PMID 36515823 3 citations (Europe PMC) Source : ORCID

  25. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

    Blood, 2023

    DOI 10.1182/blood-2023-191911 18 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  26. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000970392.99459.3a 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  27. P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000970728.42006.4a 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  28. P15 VALIDATION OF THE NOVEL EUROPEAN MYELOMA NETWORK PROGNOSTIC SCORE (R2-ISS) IN AN INDEPENDENT REAL-WORLD SETTING

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000936188.13446.94 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  29. P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000970776.33983.01 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  30. Trends in AL Amyloidosis: Decrease in Early Mortality, Increase in Survival but Less AHCT: Single Center Experience

    Transplantation and Cellular Therapy, 2023

    DOI 10.1016/s2666-6367(23)00605-x Texte intégral en libre accèsSource : OpenAlex

  31. P05 ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000936148.23905.0b Texte intégral en libre accèsSource : OpenAlex

  32. PB2213: RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000975600.58393.5d Texte intégral en libre accèsSource : OpenAlex

  33. POSTER: MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00810-8 Source : OpenAlex

  34. POSTER: MM-182 Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00806-6 Texte intégral en libre accèsSource : OpenAlex

  35. MM-182 Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01414-3 Source : OpenAlex

  36. MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01424-6 Source : OpenAlex

  37. P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01728-7 Source : OpenAlex

  38. P-133 Validation of two international myeloma staging systems: second revision of ISS and mayo additive staging sytems (MASS) in an external cohort of Ankara University

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01751-2 Source : OpenAlex

  39. P-278: Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2022

    DOI 10.1016/s2152-2650(22)00608-5 Source : OpenAlex

  40. Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model

    Transplantation and Cellular Therapy, 2022

    DOI 10.1016/s2666-6367(22)00596-6 Texte intégral en libre accèsSource : OpenAlex

  41. PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA

    HemaSphere, 2022

    DOI 10.1097/01.hs9.0000851128.52895.ec 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  42. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, 2022

    DOI 10.1016/j.jtct.2022.03.019 PMID 35306217 27 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  43. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

    The Lancet Haematology, 2022

    DOI 10.1016/s2352-3026(22)00226-5 PMID 36174641 37 citations (Europe PMC) Source : ORCID

  44. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet Haematology, 2022

    DOI 10.1016/s2352-3026(22)00103-x PMID 35550060 41 citations (Europe PMC) Source : ORCID

  45. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

    Bone Marrow Transplantation, 2022

    Source : ORCID

  46. Are Generic Imatinib Formulations Really as Effective as Originial Imatinib in Chronic Myeloid Leukemia: Real Life Data

    Research Square, 2022

    DOI 10.21203/rs.3.rs-2316364/v1 Texte intégral en libre accèsSource : ORCID

  47. Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

    Blood, 2022

    DOI 10.1182/blood-2022-169736 Source : ORCID

  48. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

    Bone Marrow Transplantation, 2022

    DOI 10.1038/s41409-022-01592-y PMID 35169284 7 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  49. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

    The Lancet Oncology, 2022

    DOI 10.1016/s1470-2045(21)00579-9 PMID 34871550 141 citations (Europe PMC) Source : ORCID

  50. Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma

    Clinical Lymphoma Myeloma and Leukemia, 2022

    Source : ORCID